Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G UVA data

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble plans to submit additional UVA efficacy data to FDA by June 1 in support of its petition to include the use of avobenzone in combination with zinc oxide or phenylbenzimidazole sulfonic acid in the final sunscreen monograph, the company tells FDA in an April 20 letter. P&G had submitted safety data on the ingredient combinations Feb. 26 following a request from the agency during an Jan. 27 "feedback" meeting ("The Tan Sheet" March 15, In Brief). FDA deemed the data "insufficient" in an April 8 letter to P&G ("The Tan Sheet" April 26, p. 9)
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS089786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel